These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22860161)

  • 21. Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers.
    Martin-Facklam M; Pizzagalli F; Zhou Y; Ostrowitzki S; Raymont V; Brašić JR; Parkar N; Umbricht D; Dannals RF; Goldwater R; Wong DF
    Neuropsychopharmacology; 2013 Feb; 38(3):504-12. PubMed ID: 23132267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans.
    Wong DF; Ostrowitzki S; Zhou Y; Raymont V; Hofmann C; Borroni E; Kumar A; Parkar N; Brašić JR; Hilton J; Dannals RF; Martin-Facklam M
    Neuroimage; 2013 Jul; 75():282-290. PubMed ID: 22155032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent β-thalassaemia.
    Taher AT; Viprakasit V; Cappellini MD; Kraus D; Cech P; Volz D; Winter E; Nave S; Dukart J; Khwaja O; Koerner A; Hermosilla R; Brugnara C
    Br J Haematol; 2021 Jul; 194(2):474-477. PubMed ID: 33931857
    [No Abstract]   [Full Text] [Related]  

  • 24. Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1.
    Cioffi CL; Wolf MA; Guzzo PR; Sadalapure K; Parthasarathy V; Dethe D; Maeng JH; Carulli E; Loong DT; Fang X; Hu M; Gupta P; Chung M; Bai M; Moore N; Luche M; Khmelnitsky Y; Love PL; Watson MA; Mhyre AJ; Liu S
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1257-61. PubMed ID: 23380375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification.
    Javitt DC
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):468-78. PubMed ID: 19562643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist.
    Brown AJ; Daniels DA; Kassim M; Brown S; Haslam CP; Terrell VR; Brown J; Nichols PL; Staton PC; Wise A; Dowell SJ
    J Pharmacol Exp Ther; 2011 Apr; 337(1):236-46. PubMed ID: 21233197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glutamate-based therapeutic approaches: inhibitors of glycine transport.
    Lechner SM
    Curr Opin Pharmacol; 2006 Feb; 6(1):75-81. PubMed ID: 16376148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurophysiological Effects of Bitopertin in Schizophrenia.
    Kantrowitz JT; Nolan KA; Epstein ML; Lehrfeld N; Shope C; Petkova E; Javitt DC
    J Clin Psychopharmacol; 2017 Aug; 37(4):447-451. PubMed ID: 28590364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycine reuptake inhibition: a promising therapeutic strategy in the treatment of schizophrenia?
    Chue PS; Baker GB
    Future Med Chem; 2013 Sep; 5(13):1475-7. PubMed ID: 24024940
    [No Abstract]   [Full Text] [Related]  

  • 31. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.
    Bridges TM; Williams R; Lindsley CW
    Curr Opin Mol Ther; 2008 Dec; 10(6):591-601. PubMed ID: 19051137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and SAR studies of novel GlyT1 inhibitors.
    Walter MW; Hoffman BJ; Gordon K; Johnson K; Love P; Jones M; Man T; Phebus L; Reel JK; Rudyk HC; Shannon H; Svensson K; Yu H; Valli MJ; Porter WJ
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5233-8. PubMed ID: 17629697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACS chemical neuroscience molecule spotlight on latuda (lurasidone; SM-13,496).
    Hopkins CR
    ACS Chem Neurosci; 2011 Feb; 2(2):58-9. PubMed ID: 22778856
    [No Abstract]   [Full Text] [Related]  

  • 34. Preclinical Reproductive and Developmental Toxicity Profile of a Glycine Transporter Type 1 (Glyt1) Inhibitor.
    Barrow P; Parrott N; Alberati D; Paehler A; Koerner A
    Birth Defects Res B Dev Reprod Toxicol; 2016 Jun; 107(3):148-56. PubMed ID: 27221585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease.
    Harada K; Nakato K; Yarimizu J; Yamazaki M; Morita M; Takahashi S; Aota M; Saita K; Doihara H; Sato Y; Yamaji T; Ni K; Matsuoka N
    Eur J Pharmacol; 2012 Jun; 685(1-3):59-69. PubMed ID: 22542656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of β-thalassemia.
    Matte A; Federti E; Winter M; Koerner A; Harmeier A; Mazer N; Tomka T; Di Paolo ML; De Falco L; Andolfo I; Beneduce E; Iolascon A; Macias-Garcia A; Chen JJ; Janin A; Lebouef C; Turrini F; Brugnara C; De Franceschi L
    JCI Insight; 2019 Nov; 4(22):. PubMed ID: 31593554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects.
    D'Souza DC; Carson RE; Driesen N; Johannesen J; Ranganathan M; Krystal JH;
    Biol Psychiatry; 2018 Sep; 84(6):413-421. PubMed ID: 29499855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials.
    Chang CH; Lin CH; Liu CY; Chen SJ; Lane HY
    J Psychopharmacol; 2020 May; 34(5):495-505. PubMed ID: 32122256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1).
    Chue P
    Curr Pharm Des; 2013; 19(7):1311-20. PubMed ID: 23194655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of GlyT1 inhibitors with improved pharmacokinetic properties.
    Wolkenberg SE; Zhao Z; Wisnoski DD; Leister WH; O'Brien J; Lemaire W; Williams DL; Jacobson MA; Sur C; Kinney GG; Pettibone DJ; Tiller PR; Smith S; Gibson C; Ma BK; Polsky-Fisher SL; Lindsley CW; Hartman GD
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1492-5. PubMed ID: 19181525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.